@article{8c843233d58542beb313652dd41cfeb5,
title = "Immune checkpoint inhibitor–induced inflammatory arthritis as a model of autoimmune arthritis",
abstract = "The development of inflammatory arthritis in patients receiving immune checkpoint inhibitor therapy is increasingly recognized due to the growing use of these drugs for the treatment of cancer. This represents an important opportunity not only to define the mechanisms responsible for the development of this immune-related adverse event and to ultimately predict or prevent its development, but also to provide a unique window into early events in the development of inflammatory arthritis. Knowledge gained through the study of this patient population, for which the inciting event is known, could shed light into the pathogenesis of autoimmune arthritis. This review will highlight the clinical and immunologic features of these entities to define common elements for future study.",
keywords = "autoimmunity, cancer, immune checkpoint inhibitor, immune-related adverse event, rheumatoid arthritis, spondyloarthropathy",
author = "Cappelli, {Laura C.} and Thomas, {Mekha A.} and Bingham, {Clifton O.} and Shah, {Ami A.} and Erika Darrah",
note = "Funding Information: This work was supported by grants from the Rheumatology Research Foundation (Innovative Research Award), Bristol‐Myers Squibb, and the National Institutes of Health (NIH; K23‐AR075872 and R01‐AR073208). The content of this paper is solely the responsibility of the authors and does not represent the official views of the NIH. Figures were created with Biorender.com and Adobe{\textregistered} Illustrator{\textregistered}. Funding Information: This work was supported by grants from the Rheumatology Research Foundation?(Innovative Research Award), Bristol-Myers Squibb, and the National Institutes of Health (NIH; K23-AR075872 and R01-AR073208). The content of this paper is solely the responsibility of the authors and does not represent the official views of the NIH. Figures were created with Biorender.com and Adobe? Illustrator?. Funding Information: LCC is a consultant for Regeneron and receives research support from Bristol‐Myers Squibb. COB is a consultant for Bristol‐Myers Squibb, Regeneron, and Genentech and receives grant support from Bristol‐Myers Squibb. ED receives grant support from Bristol‐Myers Squibb and Pfizer. The other authors declare that they have no conflicts of interest. Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2020",
month = mar,
day = "1",
doi = "10.1111/imr.12832",
language = "English (US)",
volume = "294",
pages = "106--123",
journal = "Immunological reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",
number = "1",
}